Impact of Rituximab and IPI on survival in diffuse large B cell lymphoma patients treated at a tertiary level cancer centre in Pakistan

A single-centre experience

Sohail Athar, Neelam Siddiqui, Sulaman Raza Rai, Narjis Muzaffar, Abdul Hameed

Research output: Contribution to journalArticle

Abstract

Objective: To determine the impact of Rituximab and international prognostic index score on survival in diffuse large B-cell lymphoma patients. Method: The retrospective study was conducted at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, fromJanuary to May 2013 and comprised record of patients with diffuse large B-cell lymphoma who were treated from2007 to 2010. Baseline international prognostic index score, stage at presentation were noted and the records were divided into two groups A and B on the basis of the type of chemotherapy. SPSS 19 was used for statistical analysis. Results: Of the 93 patients in the study whose records were reviewed, 54(58%) were men. Overall median age was 43 years (range: 18-76). Stages at presentation were stage-I 14 (15.1%), stage-II 41 (44.1%), stage-III 20 (21.5%) and stage-IV 18 (19.4%). International prognostic index risk categorisation was low risk 59(63.4%), low intermediate risk 23(24.7%), high intermediate risk 10(10.8%) and high risk 1(1.1%). There were 31(33%) patients in Group A and 62(67%) in Group B. Median follow-up was 3.9 years (range: 1.2-6.1). Overall survival at 4 years was 66.4%; for Group A 65.3% and for Group B 66.7% (p<0.4). On the basis of risk categories, overall survival was statistically significant (p<0.001) between the groups. Conclusion: International prognostic index risk categorisation had statistically significant impact on survival. However, there was no evidence of a significant survival benefit between types of chemotherapy. Further controlled trials are needed in this regard.

Original languageEnglish
Pages (from-to)170-174
Number of pages5
JournalJournal of the Pakistan Medical Association
Volume65
Issue number2
Publication statusPublished - 2015

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Pakistan
Survival
Neoplasms
Cancer Care Facilities
Drug Therapy
Rituximab
Retrospective Studies
Research

Keywords

  • Chemotherapy
  • Diffuse large B cell lymphoma
  • Extranodal
  • Outcome
  • Rituximab
  • Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Impact of Rituximab and IPI on survival in diffuse large B cell lymphoma patients treated at a tertiary level cancer centre in Pakistan : A single-centre experience. / Athar, Sohail; Siddiqui, Neelam; Rai, Sulaman Raza; Muzaffar, Narjis; Hameed, Abdul.

In: Journal of the Pakistan Medical Association, Vol. 65, No. 2, 2015, p. 170-174.

Research output: Contribution to journalArticle

@article{1e1ee310a95349429f47c772570fb08d,
title = "Impact of Rituximab and IPI on survival in diffuse large B cell lymphoma patients treated at a tertiary level cancer centre in Pakistan: A single-centre experience",
abstract = "Objective: To determine the impact of Rituximab and international prognostic index score on survival in diffuse large B-cell lymphoma patients. Method: The retrospective study was conducted at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, fromJanuary to May 2013 and comprised record of patients with diffuse large B-cell lymphoma who were treated from2007 to 2010. Baseline international prognostic index score, stage at presentation were noted and the records were divided into two groups A and B on the basis of the type of chemotherapy. SPSS 19 was used for statistical analysis. Results: Of the 93 patients in the study whose records were reviewed, 54(58{\%}) were men. Overall median age was 43 years (range: 18-76). Stages at presentation were stage-I 14 (15.1{\%}), stage-II 41 (44.1{\%}), stage-III 20 (21.5{\%}) and stage-IV 18 (19.4{\%}). International prognostic index risk categorisation was low risk 59(63.4{\%}), low intermediate risk 23(24.7{\%}), high intermediate risk 10(10.8{\%}) and high risk 1(1.1{\%}). There were 31(33{\%}) patients in Group A and 62(67{\%}) in Group B. Median follow-up was 3.9 years (range: 1.2-6.1). Overall survival at 4 years was 66.4{\%}; for Group A 65.3{\%} and for Group B 66.7{\%} (p<0.4). On the basis of risk categories, overall survival was statistically significant (p<0.001) between the groups. Conclusion: International prognostic index risk categorisation had statistically significant impact on survival. However, there was no evidence of a significant survival benefit between types of chemotherapy. Further controlled trials are needed in this regard.",
keywords = "Chemotherapy, Diffuse large B cell lymphoma, Extranodal, Outcome, Rituximab, Survival",
author = "Sohail Athar and Neelam Siddiqui and Rai, {Sulaman Raza} and Narjis Muzaffar and Abdul Hameed",
year = "2015",
language = "English",
volume = "65",
pages = "170--174",
journal = "JPMA. The Journal of the Pakistan Medical Association",
issn = "0030-9982",
publisher = "Pakistan Medical Association",
number = "2",

}

TY - JOUR

T1 - Impact of Rituximab and IPI on survival in diffuse large B cell lymphoma patients treated at a tertiary level cancer centre in Pakistan

T2 - A single-centre experience

AU - Athar, Sohail

AU - Siddiqui, Neelam

AU - Rai, Sulaman Raza

AU - Muzaffar, Narjis

AU - Hameed, Abdul

PY - 2015

Y1 - 2015

N2 - Objective: To determine the impact of Rituximab and international prognostic index score on survival in diffuse large B-cell lymphoma patients. Method: The retrospective study was conducted at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, fromJanuary to May 2013 and comprised record of patients with diffuse large B-cell lymphoma who were treated from2007 to 2010. Baseline international prognostic index score, stage at presentation were noted and the records were divided into two groups A and B on the basis of the type of chemotherapy. SPSS 19 was used for statistical analysis. Results: Of the 93 patients in the study whose records were reviewed, 54(58%) were men. Overall median age was 43 years (range: 18-76). Stages at presentation were stage-I 14 (15.1%), stage-II 41 (44.1%), stage-III 20 (21.5%) and stage-IV 18 (19.4%). International prognostic index risk categorisation was low risk 59(63.4%), low intermediate risk 23(24.7%), high intermediate risk 10(10.8%) and high risk 1(1.1%). There were 31(33%) patients in Group A and 62(67%) in Group B. Median follow-up was 3.9 years (range: 1.2-6.1). Overall survival at 4 years was 66.4%; for Group A 65.3% and for Group B 66.7% (p<0.4). On the basis of risk categories, overall survival was statistically significant (p<0.001) between the groups. Conclusion: International prognostic index risk categorisation had statistically significant impact on survival. However, there was no evidence of a significant survival benefit between types of chemotherapy. Further controlled trials are needed in this regard.

AB - Objective: To determine the impact of Rituximab and international prognostic index score on survival in diffuse large B-cell lymphoma patients. Method: The retrospective study was conducted at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, fromJanuary to May 2013 and comprised record of patients with diffuse large B-cell lymphoma who were treated from2007 to 2010. Baseline international prognostic index score, stage at presentation were noted and the records were divided into two groups A and B on the basis of the type of chemotherapy. SPSS 19 was used for statistical analysis. Results: Of the 93 patients in the study whose records were reviewed, 54(58%) were men. Overall median age was 43 years (range: 18-76). Stages at presentation were stage-I 14 (15.1%), stage-II 41 (44.1%), stage-III 20 (21.5%) and stage-IV 18 (19.4%). International prognostic index risk categorisation was low risk 59(63.4%), low intermediate risk 23(24.7%), high intermediate risk 10(10.8%) and high risk 1(1.1%). There were 31(33%) patients in Group A and 62(67%) in Group B. Median follow-up was 3.9 years (range: 1.2-6.1). Overall survival at 4 years was 66.4%; for Group A 65.3% and for Group B 66.7% (p<0.4). On the basis of risk categories, overall survival was statistically significant (p<0.001) between the groups. Conclusion: International prognostic index risk categorisation had statistically significant impact on survival. However, there was no evidence of a significant survival benefit between types of chemotherapy. Further controlled trials are needed in this regard.

KW - Chemotherapy

KW - Diffuse large B cell lymphoma

KW - Extranodal

KW - Outcome

KW - Rituximab

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84928232955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928232955&partnerID=8YFLogxK

M3 - Article

VL - 65

SP - 170

EP - 174

JO - JPMA. The Journal of the Pakistan Medical Association

JF - JPMA. The Journal of the Pakistan Medical Association

SN - 0030-9982

IS - 2

ER -